Cambridge Healthtech Institute’s Fourth Annual 

Managing Late Stage Research, Observational Studies and Registries: 

Overcoming Operational Challenges
February 24-25, 2015 | Hyatt Regency Orlando | Orlando, FL 

Non-interventional studies are an integral part of clinical development programs and product development plans. Product benefit risk profile, comparative effectiveness data, and health economic evidences obtained from non-interventional studies are essential for multiple stakeholders, including regulatory agencies, payers, health care management organizations, formulary inclusion decision makers, healthcare professionals, as well as patients. Cambridge Healthtech Institute’s Fourth Annual Managing Late Stage Research, Observational Studies and Registries conference is designed to facilitate knowledge exchange around all aspects of observational research, from design of non-interventional studies and their management to application of the obtained data to business and stakeholder decisions.

Tuesday | Wednesday | Track Brochure | Full Event Brochure
Stay on for Part 2: Pharmacovigilance 

Tuesday, February 24

7:30 am Registration and Morning Coffee

8:25 Opening Plenary Keynotes

9:45 Grand Opening Coffee Break in the Exhibit Hall


10:45 Chairperson’s Remarks

10:50 KEYNOTE PRESENTATION: Designing, Managing and Applying Observational Studies and Registries.

Charles BarrCharles Barr, M.D., Head, Evidence Science & Innovation, Group Medical Director, US Medical Affairs, Genentech, Inc.


11:15 Leveraging Real Word Data To Build Out Post-Market Registries

Christian ReichChristian Reich, M.D., Global Head, Discovery Informatics, AstraZeneca

This presentation will discuss how large electronic health records (EHR) databases have been increasingly used to support postmarketing studies and registries and to obtain evidence needed for pharmacoepidemiology, pharmacovigilance, comparative effectiveness research, and establishing the value of a drug for reimbursement decisions.

11:40 Observational Data Collection Studies: Considerations to Minimize Bias

Alicia GilsenanAlicia Gilsenan, Ph.D., Senior Director, Epidemiology, RTI Health Solutions

Bias is an error in design or execution of a study which produces results that are consistently distorted in one direction because of nonrandom factors. This presentation will provide tips to consider to help minimize the impact of confounding, selection bias or information bias when designing observational data collection studies. By applying proper epidemiologic methods for sampling, analysis and design observational study results can provide robust real-world data that cannot be obtained through the typical clinical trial.

PRA Health Sciences12:05 pm Presentation to be Announced



12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:15 Session Break


1:25 Chairperson’s Remarks

1:30 Increasing Late Stage Patient Recruitment through Patient-Centered Technologies

Nariman NasserNariman Nasser, Digital Strategist, Genentech

Making observational studies more accessible to patients is key to increasing recruitment and retention. In this session we will examine opportunities to better align the study experience to the daily lives of our patients.


1:55 Next-Generation Oncology Registry Management, Big Data Considerations and Applications

Jomol Mathew, Ph.D., Director, Clinical and Translational Informatics, IS, Dana-Farber Cancer Institute

Patient data registries that systematically gather longitudinal clinical data that includes family history, exposure/risk factors, health status, diseases, treatments and outcomes along with genomic/molecular profiles are important in conducting correlative studies and establishing diagnostic and prognostic markers of diseases and treatment outcomes. We will be presenting our experiences and perspectives on systems that we have developed for oncology registries at the Dana Farber Cancer Institute.

2:20 Collaborating with a regulator: EMA-commissioned risk-minimization studies

Vera Ehrenstein, MPH, DSc, Associate Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University

In 2006, the European Medicines Agency (EMA) established the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) to facilitate assessment of drug utilization and safety in Europe. Collaboration with the EMA will be illustrated from the vantage point of an ENCePP center. Topics will include preparing a competitive tender, formulating the research question, finding collaborators, and role of EMA. Guidelines for risk minimization studies will be reviewed, and risk minimization studies of antidiabetic agents will be used as examples.

2:45 Presentation to be Announced 



3:00 Refreshment Break in the Exhibit Hall

4:00 Find Your Table and Meet Your Moderator

4:05 Interactive Breakout Discussion Groups

Concurrent breakout discussion groups are interactive, guided discussions hosted by a facilitator or set of co-facilitators to discuss some of the key issues presented earlier in the day’s sessions. Delegates will join a table of interest and become an active part of the discussion at hand. To get the most out of this interactive session and format please come prepared to share examples from your work, vet some ideas with your peers, be a part of group interrogation and problem solving, and, most importantly, participate in active idea sharing.

View Detailed Interactive Breakout Discussion Groups 

5:00 Welcome Reception in the Exhibit Hall

6:15 Close of Day

Tuesday | Wednesday | Track Brochure | Full Event Brochure
Stay on for Part 2: Pharmacovigilance 

Wednesday, February 25

7:30 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:25 Plenary Keynote Session

9:45 Coffee Break in the Exhibit Hall


10:45 Chairperson’s Remarks

10:50 Using Observational Research and Registries to Support Drug Development across the Lifecycle: Pfizer’s Experience

Rachel SobelRachel Sobel, Dr.PH., Senior Director, Epidemiology - Team Lead Global Innovative Pharmaceuticals, Pfizer, Inc.

This talk will describe how epidemiologists at Pfizer use observational research and registries to support drug development across the lifecycle, with a focus on how they can be used to better understand the patient populations and safety profiles of drugs to ensure an appropriate benefit-risk balance and enable faster drug approvals and/or maintain medicine licensures. The presentation will cover some of the major regulatory frameworks and provide examples utilized at Pfizer.

11:15 CO-PRESENTATION: Registry Scope and Stakeholders: Matching Scope Feasibility With Stakeholder Needs and Expectations

Cathy KoepperCatherine (Koepper) Connelly, Director, Global Registry Operations, Genzyme, a Sanofi Company


Christian DenzelChristian Denzel, Director, Registry Programs, Genzyme, a Sanofi Company

Registry research continues to proliferate. Registries offer important research value, and associated stakeholders are often associated with multiple registry stages, such as planning and development, patient enrollment and data collection, and data reporting and publishing. While the stakeholders may be the same across stages, their needs and expectations may evolve. We will investigae how to actively support various stakeholders throughout the lifecycle of a registry, while also actively managing overall expectations and program scope.

11:40 CO-PRESENTATION: Value of the Patient Voice: Role of PROs in Pricing and Reimbursement Strategy

Kelly HollisKelly Hollis, MBA, Global Head, Surveys and Observational Studies, RTI Health Solutions


Carla DeMuroCarla DeMuro, Head, Patient Reported Outcomes, RTI Health Solutions

Patient-reported outcomes (PROs) are an accepted and often actively solicited source of evidence in evaluating and approving pharmaceutical interventions based on their clinical efficacy. Likewise, real world data including PROs plays an important role in the evaluation of the costs and benefits of new technologies. This presentation will include case studies and provide discussion on leveraging the patient voice to support pricing and reimbursement decision-making.

12:05 pm Presentation to be Announced


Speaker to be Announced

1:15 Session Break/Close of Conference

Tuesday | Wednesday | Track Brochure | Full Event Brochure
Stay on for Part 2: Pharmacovigilance 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


2015 Final Agenda Image 

> Premier Sponsors 



Drug Dev 


IMS Health  



Oracle Health Sciences(1) 

PRA Health Sciences 


> View All Sponsors 

> View Media Partners 

> Attendee Profile